FDA’s new JAK safety restrictions spell trouble for AbbVie’s Rinvoq, but to what extent?
AbbVie’s megablockbuster Rinvoq ambition suffered a blow thanks to an updated safety warning and treatment restriction from the FDA. But pharma watchers have different opinions on just how significant the impact will be on AbbVie’s JAK inhibitor. In an announcement Wednesday, the FDA is revising Rinvoq’s boxed warning to include information about increased risks of… Read More »
